MN-HISTOSONICS
HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today that the company’s Edison System has been selected to participate in the UK’s newly created Innovative Devices Access Pathway (IDAP) Pilot Program designed to accelerate the development of cost-effective medical devices and their integration into the UK market. Applications to compete for one of the 8 available places in the highly sought after UK program began in 2023 and was open to UK and international commercial and non-commercial developers with new health technology solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214369417/en/
The IDAP Pilot Program was designed and developed by a partnership of the Department of Health and Social Care, The Medicines and Healthcare products Regulatory Agency (MHRA), The National Institute for Health and Care Excellence (NICE), NHS England, Health Technology Wales, and Scottish Health Technology Group to test the IDAP pathway and to expedite the incorporation of novel medical technologies that have demonstrated the potential to meaningful address the UK’s top healthcare concerns of today, as well as in the future. The Edison Histotripsy System was measured against four distinct eligibility criteria that were required of applicants for consideration in the IDAP program. Applicants must have met the following in order to be considered for the IDAP Pilot Program: 1) the technology addresses a life-threatening or seriously debilitating condition and there is a significant patient need, 2) the technology is innovative and transformative, 3) the technology will provide system wide benefit, and 4) the technology clearly helps to address one of the following Life Sciences Vision’s Healthcare Missions. In addition to meeting the eligibility criterion set, the IDAP program enlisted patient experts in the shortlisting and selection of the eight innovative and transformative medical devices that were eventually chosen to participate.
“Selection to the IDAP program is validation of our team’s purpose of meaningfully changing the lives of patients suffering from life-threatening conditions, starting in the liver, kidney and soon in the pancreas. The criteria set forth for the IDAP Pilot Program align extremely well with our company’s goals of providing access to innovative, non-invasive treatment to all those who may benefit from histotripsy’s unique benefits across diverse health systems,” said Mike Blue, HistoSonics CEO and President. “Our experience conducting clinical trials in the UK has provided us with both the clinical outcomes and patient experiences that fulfill the rigorous criteria set by the MHRA, and we look forward to continuing the progress we’ve made in establishing the patient benefits of histotripsy across the UK,” added Blue.
The science of histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquifies targeted tissue, including tumors, at sub-cellular levels. HistoSonics' Edison System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control. The company believes that the novel mechanism of action of their proprietary technology may provide significant advantages to patients, including the ability of the treatment site to recover and resorb quickly. Uniquely, the HistoSonics’ platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today.
The Edison System is indicated for the non-invasive destruction of liver tumors, including unresectable liver tumors, using a non-thermal, mechanical process of focused ultrasound.
About HistoSonics
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN.
For more information please visit: www.histosonics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214369417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches AI-Powered News Summaries for Smarter, Faster Investment Decisions11.12.2024 16:00:00 CET | Press release
New AI Feature Provides Condensed Market Insights, Saving Time and Boosting Efficiency Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the introduction of AI-generated news summaries to its News & Research offering. This advanced feature, available at no additional cost, enables clients to access concise summaries of news articles, streamlining insights from leading providers and making it easier for investors to stay informed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211090832/en/ AI-generated News Summaries in IBKR Desktop (Graphic: Business Wire) Leveraging the power of AI, this tool extracts market-relevant information, allowing clients to quickly scan for important updates and giving them more time to make informed decisions and manage their portfolios. This, along with the ability to filter news related to stocks in portfolios and watchlists, makes it easy for users to stay
Grid Dynamics Releases Portal to Streamline Developer Experience and Boost Productivity11.12.2024 15:15:00 CET | Press release
Key Takeaways: Grid Dynamics’ developer portal enables organizations to streamline the software development process with a unified, self-service solution—improving developer productivity and reducing operational overheads. The solution provides developers with immediate access to application templates, environments, release management tools, and other essential resources. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announced the launch of its innovative developer portal. This self-service system is designed to streamline the software development lifecycle (SDLC) by providing a unified interface for managing software components, environments, and provisioning templates. It centralizes access to release management, continuous integration, incident management, and other development systems in a unified facade. The system intends to provide Grid Dynamic
SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO Services11.12.2024 15:05:00 CET | Press release
Streamlined Organization Lays Foundation for Company Rebrand SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industries, today announced the launch of a brand unification initiative. This strategic move brings together the expertise and capabilities of several industry-respected organizations under the unified SK pharmteco brand. This initiative builds on the legacies of SK biotek, SK biotek Ireland, Center for Breakthrough Medicines, Yposkesi, AMPAC Fine Chemicals, and AMPAC Analytical to create a Contract Development and Manufacturing Organization (CDMO) powerhouse. While these individual brands will continue to operate, they will now be known collectively as SK pharmteco, symbolizing a new era of innovation and growth. “By uniting under the SK pharmteco banner, we create a stronger, more streamlined organization that delivers a seamless experience for our clients,” said Joerg Ahlgrimm,
New Survey of VMware Customers Reveals Strong Desire to Maximize the Value of Perpetual Licenses11.12.2024 15:00:00 CET | Press release
With 79% of respondents indicating satisfaction with their current VMware software, most would consider continuing to utilize their perpetually licensed software if they could acquire support Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, the leading third-party support provider for Oracle, SAP and VMware software, today announced the findings of the report, “Insights and Strategies on VMware: Navigating the Evolving Hypervisor Market.” The Rimini Street-sponsored research was conducted in Q3 2024 amongst 110+ VMware customers, exploring how they are navigating changes in pricing structure and new subscription bundling since Broadcom’s acquisition of the hypervisor provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211557422/en/ New Survey of VMware Customers Reveals Strong Desire to Maximize the Value of Perpetual Licenses (Graphic: Business
SamanTree Medical Highlights Research Showing 67% Reduction in Reoperation Rates for Breast-Conserving Surgery at the 2024 SABCS11.12.2024 15:00:00 CET | Press release
SHIELD study shows reoperation rates dropped from 30% to 10% with use of the Histolog® Scanner, highlighting its potential to improve oncologic surgery and patient outcomes SamanTree Medical, a leader in oncologic surgical imaging innovation, today announced promising results from the SHIELD study, which will be presented by researchers on Dec. 12 at the 2024 San Antonio Breast Cancer Symposium (SABCS). The findings show that the Histolog® Scanner, a confocal laser microscope, reduced reoperation rates during breast-conserving surgery (BCS) from 30% to 10%, representing a 67% reduction. The innovative imaging device also demonstrated significant accuracy in detecting positive margins with high sensitivity and specificity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211957581/en/ Dr. Mariana-Felicia Sandor, first author of the SHIELD study: Reoperation Rate in Breast-Conserving Surgery using Confocal Histolog® Scanner f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom